Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03336333 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

A Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeiGene.

Active
Registry status
Phase 3
Development phase
590
Enrollment target
20
Study locations

NCT03336333: Active Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeiGene.

NCT03336333 is a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 590 participants, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (230% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03336333, a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by BeiGene.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
590 participants
Enrollment target
20
Study locations

Study Summary

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.

Primary Outcome

PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the ICR per 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines with modifications for treatment-related lymphocytosis in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with small lymphocytic lymphoma (SLL).

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions

  • DRUG Zanubrutinib
  • DRUG Venetoclax
  • DRUG Rituximab
  • DRUG Bendamustine

Study Locations (20)

New York

  • Icahn School of Medicine At Mount Sinai - New York
  • Columbia University Medical Center - New York
  • University of Rochester - Rochester

Missouri

  • Research Medical Center - Kansas City
  • Washington University - St Louis

Washington

  • Va Puget Sound Health Care System - Seattle
  • Fred Hutchinson Cancer Research Center - Seattle

New South Wales

  • Concord Repatriation General Hospital - Concord
  • The Tweed Valley Hospital - Cudgen

Georgia

  • Augusta University - Augusta

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

Trial Details

FieldValue
Enrollment Target 590 participants
Start Date 2017-10-31
Est. Completion 2027-10-31
Phase Phase 3
BeiGene

65 total trials

What the registry record for NCT03336333 still lists

NCT03336333 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (230% higher).

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.

NCT03336333 names 20 study sites across 15 states, led by New York, Missouri, Washington.

Frequently Asked Questions

What is clinical trial NCT03336333 about?

NCT03336333 is a clinical study titled "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL". To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.

What is the current status of trial NCT03336333?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2017-10-31. Estimated completion is 2027-10-31.

What conditions does trial NCT03336333 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT03336333?

The interventions under investigation include: Zanubrutinib (DRUG), Venetoclax (DRUG), Rituximab (DRUG), Bendamustine (DRUG).

Who is sponsoring clinical trial NCT03336333?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03336333 being conducted?

This trial has 20 study locations across Georgia, Illinois, Massachusetts, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03336333's enrollment target sits among peer trials

590 15th of 187 higher than 173 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01365169 · 590 participants · NA

    Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

  • NCT03774758 · 590 participants

    Biomarkers for Risk Stratification in Lung Cancer

  • NCT04747626 · 590 participants · NA

    B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair

  • NCT05722938 · 590 participants · Phase 3

    Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03336333, the US trial registry maintained by the National Library of Medicine. NCT03336333 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.